• Profile
Close

Effect of hemodialysis on efficacy and pharmacokinetics of sofosbuvir coformulated with either daclatasvir or ledipasvir in patients with end-stage renal disease

Blood Purification Apr 17, 2020

Lin T, Wang X, Gao H, et al. - Researchers performed this study among hemodialysis (HD) patients in order to assess the pharmacokinetic characteristics as well as the effectiveness of daclatasvir/sofosbuvir (DAC/SOF) and ledipasvir/SOF (LDV/SOF) in this patient population. They treated 7 patients with SOF coadministered with DAC or LDV once daily for 12 weeks. Six (100%) patients successfully achieved a sustained virologic response in week 12 (SVR12), except for the death of 1 patient because of severe cerebral hemorrhage not associated with antiviral therapy. The extraction ratio of SOF007 was estimated to be 66.67%, and the HD clearance of SOF007 was identified to be 5.65 L/h. Findings revealed not only the good tolerability but also the effectiveness of the combination of SOF with either DAC or LDV to afford high SVR12 in HD patients.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay